<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients with relapsed diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>) who have failed or are ineligible for autologous haematopoietic cell transplantation (HCT) have a poor prognosis </plain></SENT>
<SENT sid="1" pm="."><plain>We examined the outcomes of non-myeloablative allogeneic HCT in this setting </plain></SENT>
<SENT sid="2" pm="."><plain>Thirty-one patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> and one patient with Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> received allogeneic HCT following 2 Gy total body irradiation with or without fludarabine </plain></SENT>
<SENT sid="3" pm="."><plain>Median age was 52 years </plain></SENT>
<SENT sid="4" pm="."><plain>Twenty-four patients (75%) had undergone prior autologous HCT </plain></SENT>
<SENT sid="5" pm="."><plain>Disease status at HCT was complete response (14/32, 44%), partial response (9/32, 28%), or refractory (9/32, 28%) </plain></SENT>
<SENT sid="6" pm="."><plain>Cumulative incidences of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) grades II-IV, grades III-IV, and <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD were 53%, 19%, and 47% respectively </plain></SENT>
<SENT sid="7" pm="."><plain>With a median follow-up of 45 months, 3-year estimated overall (OS) and progression-free survival (PFS) was 45% and 35% respectively </plain></SENT>
<SENT sid="8" pm="."><plain>Three-year cumulative incidences of relapse and non-relapse mortality were 41% and 25% respectively </plain></SENT>
<SENT sid="9" pm="."><plain>In multivariate models, chemosensitive disease and receipt of &gt;or=4 lines of treatment before HCT were associated with better OS </plain></SENT>
<SENT sid="10" pm="."><plain>Patients with chemosensitive disease had 3-year OS and PFS of 56% and 43% respectively </plain></SENT>
<SENT sid="11" pm="."><plain>Non-myeloablative allogeneic HCT can produce long-term disease-free survival in patients with chemosensitive relapsed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> who have failed or are ineligible for autologous HCT </plain></SENT>
</text></document>